Innate Pharma/AstraZeneca $1.275 billion joint venture

Overview:

• Innate Pharma and AstraZeneca formed a $1.275 billion joint venture to develop prospective cancer treatments like Innate Pharma’s IPH2201 antibody. 
• AstraZeneca agreed to pay Innate Pharma $250 million. In return, AstraZeneca was to receive consideration for exclusive global rights to to co-develop and commercialise IPH2201 in combination with MEDI4736.
• The agreement also stated that AstraZeneca was to receive access to IPH2201 in monotherapy.
• At the time of the agreement, IPH2201 was in Phase II. According to the agreement, AstraZeneca was also to pay $100 million before the commencement of Phase III.
• The agreement gave Innate the right to co-promote in Europe for a 50% profit share.

Rani Mehta - Journalist